Patents by Inventor Arthur Kluge

Arthur Kluge has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF
    Publication number: 20190084958
    Abstract: Provided herein are compounds I, II or III and compositions useful in increasing PPAR8 activity. The compounds and compositions provided herein are useful for the treatment of PPAR8 related diseases (e.g., muscular diseases, vascular disease, demyelinating disease, and metabolic diseases).
    Type: Application
    Filed: October 5, 2016
    Publication date: March 21, 2019
    Applicants: Mitobridge, Inc., The Salk Institute for Biological Studies
    Inventors: Michael Downes, Ronald M. Evans, Arthur Kluge, Bharat Lagu, Masanori Miura, Sunil Kumar Panigrahi, Michael Patane, Susanta Samajdar, Ramesh Senaiar, Taisuke Takahashi
  • NICOTINAMIDE RIBOSIDE AND NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES FOR USE IN THE TREATMENTS OF MITOCHONDRIAL-RELATED DISEASES
    Publication number: 20190085008
    Abstract: Provided herein are compounds of Formula (I): or a pharmaceutically acceptable salt thereof, and compositions comprising such compounds that are useful for increasing the amount of NAD+ in cells. Also disclosed are methods of using the disclosed compounds and compositions for treating mitochondrial-related diseases or disorders.
    Type: Application
    Filed: November 2, 2016
    Publication date: March 21, 2019
    Applicant: Mitobridge, Inc.
    Inventors: Arthur Kluge, Nan Ji
  • PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof
    Patent number: 10188627
    Abstract: Provided herein are compounds of formula (I) useful for the treatment of PPAR-delta related diseases (e.g. mitochondrial diseases, muscular diseases, vascular diseases, demyelinating diseases and metabolic diseases).
    Type: Grant
    Filed: October 7, 2015
    Date of Patent: January 29, 2019
    Assignees: Mitobridge, Inc., Salk Institute for Biological Studies
    Inventors: Michael Downes, Ronald Evans, Arthur Kluge, Bharat Lagu, Masanori Miura, Sunil Kumar Panigrahi, Michael Patane, Susanta Samajdar, Ramesh Senaiar, Taisuke Takahashi
  • PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF
    Publication number: 20170304255
    Abstract: Provided herein are compounds of formula (I) useful for the treatment of PPAR-delta related diseases (e.g. mitochondrial diseases, muscular diseases, vascular diseases, demyelinating diseases and metabolic diseases).
    Type: Application
    Filed: October 7, 2015
    Publication date: October 26, 2017
    Inventors: Thomas Baiga, Michael Downes, Ronald Evans, Arthur Kluge, Bharat Lagu, Masanori Miura, Sunil Kumar Panigrahi, Michael Patane, Susanta Samajdar, Ramesh Senaiar, Taisuke Takahashi
  • PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF
    Publication number: 20170305894
    Abstract: Provided herein are compounds of Formula (I) and compositions useful in increasing PPARS activity. The compounds and compositions provided herein are useful for the treatment of PPARS related diseases (e.g., muscular diseases, vascular disease, demyelinating disease, and metabolic diseases).
    Type: Application
    Filed: October 7, 2015
    Publication date: October 26, 2017
    Inventors: Thomas Baiga, Michael Downes, Ronald Evans, Arthur Kluge, Bharat Lagu, Masanori Miura, Sunil Kumar Panigrahi, Michael Patane, Susanta Samajdar, Ramesh Senaiar, Taisuke Takahashi
  • Protein Kinase Conjugates and Inhibitors
    Publication number: 20170174691
    Abstract: The invention relates to protein conjugates that contain a protein kinase containing a cysteine residue in the ATP binding site and an inhibitor that is covalently and irreversibly bonded to said cysteine residue, such that the activity of the protein kinase is irreversibly inhibited. The invention also relates to compounds that irreversibly inhibit protein kinases.
    Type: Application
    Filed: July 18, 2016
    Publication date: June 22, 2017
    Inventors: Juswinder Singh, Russell Colyn Petter, Deqiang Niu, Lixin Qiao, Arthur Kluge, Roy Lobb, Shomir Ghosh, Zhendong Zhu
  • Protein kinase conjugates and inhibitors
    Patent number: 9556426
    Abstract: The invention relates to protein conjugates that contain a protein kinase containing a cysteine residue in the ATP binding site and an inhibitor that is covalently and irreversibly bonded to said cysteine residue, such that the activity of the protein kinase is irreversibly inhibited. The invention also relates to compounds that irreversibly inhibit protein kinases.
    Type: Grant
    Filed: September 15, 2010
    Date of Patent: January 31, 2017
    Assignee: Celgene Avilomics Research, Inc.
    Inventors: Juswinder Singh, Russell Colyn Petter, Deqiang Niu, Lixin Qiao, Arthur Kluge, Roy Lobb, Shomir Ghosh, Zhendong Zhu
  • 4,6-disubstituted pyrimidines as kinase inhibitors
    Patent number: 9393246
    Abstract: The present invention provides 4,6-disubstituted pyrimidine compounds useful as kinase inhibitors, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Grant
    Filed: April 22, 2015
    Date of Patent: July 19, 2016
    Assignee: Celgene Avilomics Research, Inc.
    Inventors: Juswinder Singh, Shomir Ghosh, Arthur Kluge, Russell C. Petter, Richland W. Tester
  • HETEROARYL COMPOUNDS AND USES THEREOF
    Publication number: 20150328223
    Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Application
    Filed: April 22, 2015
    Publication date: November 19, 2015
    Inventors: Juswinder Singh, Shomir Ghosh, Arthur Kluge, Russell C. Petter, Richland W. Tester
  • 4,6-disubstituted pyrimidines useful as kinase inhibitors
    Patent number: 9040541
    Abstract: The present invention provides 4,6-disubstituted pyrimidine compounds useful as kinase inhibitors, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Grant
    Filed: May 2, 2013
    Date of Patent: May 26, 2015
    Assignee: Celgene Avilomics Research, Inc.
    Inventors: Juswinder Singh, Shomir Ghosh, Arthur Kluge, Russell C. Petter, Richland W. Tester
  • RAF INHIBITORS
    Publication number: 20110257207
    Abstract: The present invention provides derivatives of pyrido[2,3-d]pyrimidin-7-one. These compounds are inhibitors or kinases such as Raf, including compounds that show anti-proliferative activity, including against tumor cells, and are useful in the treatment of diseases including cancer.
    Type: Application
    Filed: May 12, 2011
    Publication date: October 20, 2011
    Applicants: Agennix USA Inc, Agennix AG
    Inventors: Alexander BACKES, Joachim VOGT, Peter AMON, Igor IVANOV, Stefan HANNUS, Matthias BORGMANN, Kerrin HANSEN, Rebecca CASAUBON, Chase SMITH, Krishna MURTHI, Arthur KLUGE, Andreas SCHOOP, Lars NEUMANN, Jan EICKHOFF
  • Protein Kinase Conjugates and Inhibitors
    Publication number: 20110117073
    Abstract: The invention relates to protein conjugates that contain a protein kinase containg a cysteine residue in the ATP binding site and an inhibitor that is covalently and irreversibly bonded to said cysteine residue, such that the activity of the protein kinase is irreversibly inhibited. The invention also relates to compounds that irreversibly inhibit protein kinases.
    Type: Application
    Filed: September 15, 2010
    Publication date: May 19, 2011
    Applicant: Avila Therapeutics, Inc.
    Inventors: Juswinder Singh, Russell Colyn Petter, Deqiang Niu, Lixin Qiao, Arthur Kluge, Roy Lobb, Shomir Ghosh, Zhendong Zhu
  • Inhibitors of cyclin-dependent kinases, compositions and uses related thereto
    Patent number: 7893057
    Abstract: The invention pertains to novel cyclin dependent kinase inhibitors (cdks) and specifically, but not exclusively, as inhibitors of cdk/cyclin complexes. As described herein, the inhibitors of this invention are capable of inhibiting the cell-cycle machinery and consequently may be useful in modulating cell-cycle progression, ultimately controlling cell growth and differentiation. Such compounds would be useful for treating subjects having disorders associated with excessive cell proliferation.
    Type: Grant
    Filed: June 18, 2009
    Date of Patent: February 22, 2011
    Assignee: Agennix USA Inc.
    Inventors: Nicholas Bockovich, Arthur Kluge, Chris Oalmann, Krishna K. Murthi, Siya Ram, Zhongguo Wang, Jianxing Huang
  • Inhibitors of cyclin-dependent kinases, compositions and uses related thereto
    Publication number: 20100004207
    Abstract: The invention pertains to novel cyclin dependent kinase inhibitors (cdks) and specifically, but not exclusively, as inhibitors of cdk/cyclin complexes. As described herein, the inhibitors of this invention are capable of inhibiting the cell-cycle machinery and consequently may be useful in modulating cell-cycle progression, ultimately controlling cell growth and differentiation. Such compounds would be useful for treating subjects having disorders associated with excessive cell proliferation.
    Type: Application
    Filed: June 18, 2009
    Publication date: January 7, 2010
    Inventors: Nicholas Bockovich, Arthur Kluge, Chris Oalmann, Krishna K. Murthi, Siya Ram, Zhongguo Wang, Jianxing Huang
  • Inhibitors of cyclin-dependent kinases, compositions and uses related thereto
    Publication number: 20050090471
    Abstract: The invention pertains to novel cyclin dependent kinase inhibitors (cdks) and specifically, but not exclusively, as inhibitors of cdk/cyclin complexes. As described herein, the inhibitors of this invention are capable of inhibiting the cell-cycle machinery and consequently may be useful in modulating cell-cycle progression, ultimately controlling cell growth and differentiation. Such compounds would be useful for treating subjects having disorders associated with excessive cell proliferation.
    Type: Application
    Filed: October 15, 2002
    Publication date: April 28, 2005
    Applicants: GPC Biotech, Inc, GPC Biotech AG
    Inventors: Nicholas Bockovich, Arthur Kluge, Siya Ram, Zhongguo Wang, Chris Oalmann, Krishna Murthi, Frank Becker
  • Inhibitors of cyclin-dependent kinases, compositions and uses related thereto
    Publication number: 20040266853
    Abstract: The invention pertains to novel cyclin dependent kinase inhibitors (cdks) and specifically, but not exclusively, as inhibitors of cdk/cyclin complexes. As described herein, the inhibitors of this invention are capable of inhibiting the cell-cycle machinery and consequently may be useful in modulating cell-cycle progression, ultimately controlling cell growth and differentiation. Such compounds would be useful for treating subjects having disorders associated with excessive cell proliferation.
    Type: Application
    Filed: April 6, 2004
    Publication date: December 30, 2004
    Applicant: GPC Biotech, Inc.
    Inventors: Nicholas Bockovich, Arthur Kluge, Chris Oalmann, Krishna K. Murthi, Siya Ram, Zhongguo Wang, Jianxing Huang
  • Inhibitors of cyclin-dependent kinases, compositions and uses related thereto
    Publication number: 20040266854
    Abstract: The invention pertains to novel cyclin dependent kinase inhibitors (cdks) and specifically, but not exclusively, as inhibitors of cdk/cyclin complexes. As described herein, the inhibitors of this invention are capable of inhibiting the cell-cycle machinery and consequently may be useful in modulating cell-cycle progression, ultimately controlling cell growth and differentiation. Such compounds would be useful for treating subjects having disorders associated with excessive cell proliferation.
    Type: Application
    Filed: April 7, 2004
    Publication date: December 30, 2004
    Applicants: GPC Biotech, Inc., GPC Biotech AG
    Inventors: Frank Becker, Nicholas Bockovich, Jon H. Come, Arthur Kluge, Krishna K. Murthi, Chris Oalmann, Siya Ram, Zhongguo Wang
  • Compositions and methods for inhibiting prenyltransferases
    Publication number: 20040235798
    Abstract: The present invention relates in part to compositions and methods for inhibiting prenyltransferases.
    Type: Application
    Filed: May 7, 2004
    Publication date: November 25, 2004
    Inventors: Krishna K Murthi, Arthur Kluge
  • Inhibitors of cyclin-dependent kinases, compositions and uses related thereto
    Patent number: 6753329
    Abstract: The invention pertains to novel cyclin dependent kinase inhibitors (cdks) and specifically, but not exclusively, as inhibitors of cdk/cyclin complexes. As described herein, the inhibitors of this invention are capable of inhibiting the cell-cycle machinery and consequently may be useful in modulating cell-cycle progression, ultimately controlling cell growth and differentiation. Such compounds would be useful for treating subjects having disorders associated with excessive cell proliferation.
    Type: Grant
    Filed: December 17, 2002
    Date of Patent: June 22, 2004
    Assignees: GPC Biotech Inc., GPC Biotech AG
    Inventors: Nicholas Bockovich, Arthur Kluge, Chris Oalmann, Krishna K. Murthi, Frank Becker
  • Inhibitors of cyclin-dependent kinases, compositions and uses related thereto
    Publication number: 20030162797
    Abstract: The invention pertains to novel cyclin dependent kinase inhibitors (cdks) and specifically, but not exclusively, as inhibitors of cdk/cyclin complexes. As described herein, the inhibitors of this invention are capable of inhibiting the cell-cycle machinery and consequently may be useful in modulating cell-cycle progression, ultimately controlling cell growth and differentiation. Such compounds would be useful for treating subjects having disorders associated with excessive cell proliferation.
    Type: Application
    Filed: December 17, 2002
    Publication date: August 28, 2003
    Inventors: Nicholas Bockovich, Arthur Kluge, Siya Ram, Zhonghuo Wang, Chris Oalmann, Krishna K. Murthi